These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6316671)

  • 1. [In-vitro activity of cefotaxime].
    Knothe H
    Wien Klin Wochenschr Suppl; 1983; 142():4-7. PubMed ID: 6316671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical use of new cephalosporins for severe infections in internal medicine].
    Stille W
    Wien Klin Wochenschr Suppl; 1983; 142():18-20. PubMed ID: 6316668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cefotaxime, moxalactam and ceftriaxone: comparison of in vitro activity against hospital strains of Enterobacteriaceae belonging to the 4 principal phenotypes of sensitivity to beta-lactams].
    Jarlier V; Bismuth R; Grosset J
    Pathol Biol (Paris); 1983 May; 31(5):336-42. PubMed ID: 6312393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of temocillin, moxalactam and cefotaxime against gram negative bacteria sensitive or resistant to ureidopenicillins and/or cefacedone.
    Bartmann K; Tarbuc R
    Zentralbl Bakteriol Mikrobiol Hyg A; 1983 Dec; 256(2):202-10. PubMed ID: 6324518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of cefotaxime, latamoxef and ceftriaxone on hospital strains of Enterobacteriaceae resistant to cefalotine and cefoxitine].
    Berche P; Gaillard JL
    Ann Biol Clin (Paris); 1986; 44(6):624-7. PubMed ID: 3826779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro activity of cefotaxime against enterobacteriaceae. Comparison with cephalothin, cefazolin, cefamandole, cefoxitin and cefuroxime on 117 strains isolated from neutropenic patients (author's transl)].
    Tancrede C; Mariel C; Chaigneau H; Eveno J
    Nouv Presse Med; 1981 Feb; 10(8):545-7. PubMed ID: 6259589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of cefotaxime against enterococci.
    Moellering RC; Eliopoulos GM
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):85S-90S. PubMed ID: 6086221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity and beta-lactamase stability of moxalactam and other selected cephalosporin antibiotics.
    Vuye A
    Arzneimittelforschung; 1981; 31(8):1290-5. PubMed ID: 6457607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cefotaxime in bronchopulmonary infections (author's transl)].
    Kermarec J; Sauvaget J
    Nouv Presse Med; 1981 Feb; 10(8):650-3. PubMed ID: 6259612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute.
    Kumar MS; Lakshmi V; Rajagopalan R
    Indian J Med Microbiol; 2006 Jul; 24(3):208-11. PubMed ID: 16912442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases.
    Sanders CC
    J Chemother; 1996 Feb; 8 Suppl 2():57-62. PubMed ID: 8738847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of anaerobic bacteria to cefoperazone and other beta-lactam antibiotics.
    Jacobus NV; Tally FP; Barza M; Gorbach SL
    Clin Ther; 1980; 3(Spec Issue):34-8. PubMed ID: 6446396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to cefamandole: a collaborative study of emerging clinical problems.
    Sanders CC; Moellering RC; Martin RR; Perkins RL; Strike DG; Gootz TD; Sanders WE
    J Infect Dis; 1982 Jan; 145(1):118-25. PubMed ID: 6274965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility testing accuracy of a CTX-M-type extended-spectrum beta-lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 beta-lactams.
    Pottumarthy S; Yu Y; Sader HS; Jones RN; Chen M
    Diagn Microbiol Infect Dis; 2005 Oct; 53(2):131-41. PubMed ID: 15939566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
    Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The newest cephalosporins: how to use them?
    Ehrenkranz NJ; Hoffman TA
    J Fla Med Assoc; 1982 Oct; 69(10):863-4. PubMed ID: 6292322
    [No Abstract]   [Full Text] [Related]  

  • 19. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates.
    Nijssen S; Florijn A; Bonten MJ; Schmitz FJ; Verhoef J; Fluit AC
    Int J Antimicrob Agents; 2004 Dec; 24(6):585-91. PubMed ID: 15555882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of some streptococci strains of anginosus group isolated from oral and maxillofacial infections.
    Băncescu G; Skaug N; Dumitriu S; Băncescu A
    Roum Arch Microbiol Immunol; 1999; 58(1):57-63. PubMed ID: 11845446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.